Business Wire

Save Money While Seeking the Sun: Cost Effective Winter Stays in Egypt

25.1.2023 11:00:00 EET | Business Wire | Press release

Share

Spending the winter season in a warm place has always been popular, whether you’re a digital nomad or a pensioner. But, the rising cost of living over the past year could cause many to reconsider whether, or how, they travel.

While Egypt has long been on travelers’ radar, thanks to its low-cost of living, it has now become a popular long-stay winter destination. In fact, a one month stay in a luxurious three or four-star-hotel can cost less than living in the Western European countries for the same amount of time.

Research collated by the Egyptian Government from a variety of tour operators shows a four-week winter sun stay costs, on average, €1 218 per couple. This includes 160€ per person for a return flight, 25€ per couple for a double room in a four-star hotel and 8€ per person for a three-course dinner at a local restaurant.

In comparison, the average monthly cost of a two-person household for gas, energy, food and beverages is 1 396€ in Italy, 1 509€ in France and 1 601€ in Germany during the winter.

The Egyptian Government is currently promoting and facilitating month long stays at a wide variety of hotels.

Amr El-Kady, CEO of Egyptian Tourism Authority, said: “Egypt is always happy to welcome travelers from Europe. We are doing our best to make the stay as effortless and affordable as possible. This winter season, we invite you to spend the cold months under the kind Egyptian sun, saving the budget and filling life with fantastic new experiences”.

What does Egypt have to offer? Plenty.

From Cairo to Luxor, from the beguiling desert to the lush delta of the Nile, Egypt is a traveler's dream. Whether diving into the rich underwater world of the Red Sea, sailing on the Nile towards the sunset or tracing the secrets of the ancient Egyptians in stunning temple complexes, the land of the pharaohs has something to offer to every visitor.

Among the most famous destinations is the capital Cairo, where you can immerse yourself in all eras of Egyptian history in the Egyptian Museum, and visit the famous Pyramids of Giza with the impressive Sphinx. Another highlight is the city of Luxor, which offers some spectacular wonders, that include the Valley of the Kings, the Temple of Karnak and the legendary Luxor Temple, which is one of the absolute must-sees on any trip and continues to enchant with ancient stories.

If you prefer active and adventurous activities, you don't have to look far. Egypt is not only a diver's paradise, but also offers desert excursions, Nile cruises and breathtaking landscapes such as the Colored Canyon National Park on the Sinai Peninsula. While ecotourism is becoming increasingly popular in the country and even spiritual tours are offered, Egypt is also known for particularly high-quality spa treatments.

A variety of flight connections ensure a pleasant way to get there. There are direct flights to resorts of Egypt from almost every major European city.

Find out what else Egypt has to offer on Egypt travel - Home (experienceegypt.eg)

- ENDS –

Destination images can be downloaded here

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

External Press office
Philipp Koneev, Senior Account Manager, MC Group
p.koneev@mcgroup.com
+49 30 65000‑540

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye